The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global blood culture test market reached a value of US$ 4.3 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.1 Billion by 2027, exhibiting a CAGR of 8.77% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
A blood culture test refers to a medical procedure that is conducted to diagnose bacterial, fungal and mycobacterial infections. It is performed for the identification of various microorganisms in the blood sample and for preventing the development of sepsis conditions. The results of the culture test can aid in determining the specific pathogens that are causing the infection and possible ways for combating the disease. It utilizes products including blood culture media, assay kits, reagents, and blood culture accessories, and instruments such as automated blood culture systems and supporting laboratory equipment.
The increasing prevalence of chronic and infectious diseases across the globe is one of the key factors driving the growth of the market. Furthermore, the growing geriatric population that is more susceptible to sepsis and other medical ailments is also providing a boost to the market growth. Additionally, the growing demand for blood culture tests to analyze specimens, due to the outbreak of the COVID-19 pandemic, is acting as another major growth-inducing factor. Laboratories, diagnostic centers and other healthcare institutes are now increasingly using these tests for detecting the presence of antibodies in the blood and identifying and isolating the infected individuals. Other factors, including the rising health consciousness among the masses, improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global blood culture test market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on testing medthod, product, technology, application and end-user.
Breakup by Testing Method:
Breakup by Product:
Breakup by Technology:
Breakup by Application:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Danaher Corporation, Becton, Dickinson and Company, bioMeriux SA, Bruker Corporation, Luminex Corporation, Merck KGaA, Siemens Healthcare GmbH, F.Hoffmann-La Roche Ltd., T2 Biosystems Inc. and Thermo Fisher Scientific Company.
|Base Year of the Analysis||2021|
|Segment Coverage||Testing Method, Product, Technology, Application, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Danaher Corporation, Becton, Dickinson and Company, bioMeriux SA, Bruker Corporation, Luminex Corporation, Merck KGaA, Siemens Healthcare GmbH, F.Hoffmann-La Roche Ltd., T2 Biosystems Inc. and Thermo Fisher Scientific Company|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global blood culture test market was valued at US$ 4.3 Billion in 2021.
We expect the global blood culture test market to exhibit a CAGR of 8.77% during 2022-2027.
The high prevalence of several infectious diseases, along with the growing demand for blood culture tests in determining the specific pathogens causing the infection and identifying their possible treatments, is primarily driving the global blood culture test market.
The sudden outbreak of the COVID-19 pandemic has led to the increasing demand for blood culture tests to analyze specimens, detect the presence of antibodies in the blood, and identify and isolate the COVID-19-infected patients.
Based on the testing method, the global blood culture test market can be segmented into conventional and automated. Currently, conventional holds the majority of the total market share.
Based on the product, the global blood culture test market has been divided into consumables, instruments, and software and services. Among these, consumables currently exhibit a clear dominance in the market.
Based on the technology, the global blood culture test market can be categorized into culture-based technology, molecular technology, proteomic technology, and others. Currently, culture-based technology accounts for the majority of the global market share.
Based on the application, the global blood culture test market has been segregated into bacterial infections, fungal infections, and mycobacterial infections, where bacterial infections currently hold the largest market share.
Based on the end user, the global blood culture test market can be bifurcated into hospital laboratories, reference laboratories, research laboratories, and others. Currently, hospital laboratories exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global blood culture test market include Abbott Laboratories, Danaher Corporation, Becton, Dickinson and Company, bioMeriux SA, Bruker Corporation, Luminex Corporation, Merck KGaA, Siemens Healthcare GmbH, F.Hoffmann-La Roche Ltd., T2 Biosystems Inc., and Thermo Fisher Scientific Company.
Home Healthcare Market by Product (Therapeutic Products, Testing, Screening, and Monitoring Products, Mobility Care Products), Service (Skilled Nursing, Rehabilitation Therapy, Hospice & Palliative Care, Unskilled Care, Respiratory Therapy, Infusion Therapy, Pregnancy Care), Indication (Cancer, Respiratory Diseases, Movement Disorders, Cardiovascular Diseases & Hypertension, Pregnancy, Wound Care, Diabetes, Hearing Disorders, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at